BACKGROUND: Coronary artery disease remains the leading cause of morbidity and mortality in women. The optimal non-invasive test for evaluation of ischemic heart disease in women is unknown. Although current guidelines support the choice of the exercise tolerance test (ETT) as a first line test for women with a normal baseline ECG and adequate exercise capabilities, supportive data for this recommendation are controversial. OBJECTIVE: The what is the optimal method for ischemia evaluation in women? (WOMEN) study was designed to determine the optimal non-invasive strategy for CAD risk detection of intermediate and high risk women presenting with chest pain or equivalent symptoms suggestive of ischemic heart disease. The study will prospectively compare the 2-year event rates in women capable of performing exercise treadmill testing or Tc-99 m tetrofosmin SPECT myocardial perfusion imaging (MPI). METHODS/STUDY DESIGN: The study will enroll women presenting for the evaluation of chest pain or anginal equivalent symptoms who are capable of performing >5 METs of exercise while at intermediate-high pretest risk for ischemic heart disease who will be randomized to eitherETT testing alone or with Tc-99 m tetrofosmin SPECT MPI. The null hypothesis for this project is that the exercise ECG has the same negative predictive value for risk detection as gated myocardial perfusion SPECT in women. The primary aim is to compare 2-year cardiac event rates in women randomized to SPECT MPI to those randomized to ETT. CONCLUSIONS: The WOMEN study seeks to provide objective information for guidelines for the evaluation of symptomatic women with an intermediate-high likelihood for CAD.
RCT Entities:
BACKGROUND:Coronary artery disease remains the leading cause of morbidity and mortality in women. The optimal non-invasive test for evaluation of ischemic heart disease in women is unknown. Although current guidelines support the choice of the exercise tolerance test (ETT) as a first line test for women with a normal baseline ECG and adequate exercise capabilities, supportive data for this recommendation are controversial. OBJECTIVE: The what is the optimal method for ischemia evaluation in women? (WOMEN) study was designed to determine the optimal non-invasive strategy for CAD risk detection of intermediate and high risk women presenting with chest pain or equivalent symptoms suggestive of ischemic heart disease. The study will prospectively compare the 2-year event rates in women capable of performing exercise treadmill testing or Tc-99 m tetrofosmin SPECT myocardial perfusion imaging (MPI). METHODS/STUDY DESIGN: The study will enroll women presenting for the evaluation of chest pain or anginal equivalent symptoms who are capable of performing >5 METs of exercise while at intermediate-high pretest risk for ischemic heart disease who will be randomized to either ETT testing alone or with Tc-99 m tetrofosmin SPECT MPI. The null hypothesis for this project is that the exercise ECG has the same negative predictive value for risk detection as gated myocardial perfusion SPECT in women. The primary aim is to compare 2-year cardiac event rates in women randomized to SPECT MPI to those randomized to ETT. CONCLUSIONS: The WOMEN study seeks to provide objective information for guidelines for the evaluation of symptomatic women with an intermediate-high likelihood for CAD.
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: Lori Mosca; Carole L Banka; Emelia J Benjamin; Kathy Berra; Cheryl Bushnell; Rowena J Dolor; Theodore G Ganiats; Antoinette S Gomes; Heather L Gornik; Clarissa Gracia; Martha Gulati; Constance K Haan; Debra R Judelson; Nora Keenan; Ellie Kelepouris; Erin D Michos; L Kristin Newby; Suzanne Oparil; Pamela Ouyang; Mehmet C Oz; Diana Petitti; Vivian W Pinn; Rita F Redberg; Rosalyn Scott; Katherine Sherif; Sidney C Smith; George Sopko; Robin H Steinhorn; Neil J Stone; Kathryn A Taubert; Barbara A Todd; Elaine Urbina; Nanette K Wenger Journal: Circulation Date: 2007-02-19 Impact factor: 29.690
Authors: T H Marwick; L J Shaw; M S Lauer; K Kesler; R Hachamovitch; G V Heller; M I Travin; S Borges-Neto; D S Berman; D D Miller Journal: Am J Med Date: 1999-02 Impact factor: 4.965
Authors: Jennifer H Mieres; Leslee J Shaw; Andrew Arai; Matthew J Budoff; Scott D Flamm; W Gregory Hundley; Thomas H Marwick; Lori Mosca; Ayan R Patel; Miguel A Quinones; Rita F Redberg; Kathryn A Taubert; Allen J Taylor; Gregory S Thomas; Nanette K Wenger Journal: Circulation Date: 2005-02-01 Impact factor: 29.690
Authors: R Hachamovitch; D S Berman; H Kiat; C N Bairey; I Cohen; A Cabico; J Friedman; G Germano; K F Van Train; G A Diamond Journal: J Am Coll Cardiol Date: 1996-07 Impact factor: 24.094
Authors: Leslee J Shaw; Robert Hendel; Salvador Borges-Neto; Michael S Lauer; Naomi Alazraki; Joy Burnette; Elizabeth Krawczynska; Manuel Cerqueira; Jamshid Maddahi Journal: J Nucl Med Date: 2003-02 Impact factor: 10.057
Authors: Pamela S Douglas; Allen Taylor; Diane Bild; Robert Bonow; Philip Greenland; Michael Lauer; Frank Peacock; James Udelson Journal: J Am Soc Echocardiogr Date: 2009-07 Impact factor: 5.251
Authors: Sahar S Abdelmoneim; Mathieu Bernier; Mary E Hagen; Susan Eifert-Rain; Dalene Bott-Kitslaar; Susan Wilansky; Ramon Castello; Gajanan Bhat; Patricia A Pellikka; Patricia J M Best; Sharonne N Hayes; Sharon L Mulvagh Journal: J Womens Health (Larchmt) Date: 2013-02 Impact factor: 2.681